Allergy Thera. Regulatory News (AGY)

27 July 2015

Allergy Therapeutics plc

Director Share Dealings

On 24 July 2015, the Board of Allergy Therapeutics plc ("Allergy Therapeutics" or "the Company") was informed that on 24 July 2015, Manuel Llobet, Chief Executive Officer, purchased 50,000 ordinary shares of 0.10p ("Ordinary Shares") at a price of 24.45p per share. Mr Llobet's beneficial holding now stands at 3,175,000 Ordinary Shares, which represents 0.58% of the issued share capital of the Company to which voting rights are attached.

- Ends -

For further information:

Note to editors:

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.